| INTRODUCTION
Cholangiocarcinoma accounts for 3% of gastrointestinal malignancies worldwide, with 3500 cases diagnosed per year in the United States, the majority of which (60-80%) arise in the perihilar region. 1, 2 Unresectable disease has a dismal prognosis, with a median survival of less than 1 year. 1, 3 Margin negative R0 resection provides the only chance for long-term cure. 3, 4 Despite this, resectable disease has a 5-year survival between 20% and 50%. 3, [5] [6] [7] Adjuvant therapy (AT) has been advocated after resected hilar cholangiocarcinoma (HC) to improve outcomes. [8] [9] [10] The role of AT for resected HC is a source of significant debate.
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Current National Comprehensive Cancer Network (NCCN) guidelines for AT in resected HC comment that more data are necessary in order to make firm conclusions. 12 In two recent retrospective reviews of AT in biliary tract cancer (BTC), no survival benefit was found. 7, 13 Conversely, within the last 10 years three single center retrospective studies have demonstrated a survival benefit with AT in resected extrahepatic cholangiocarcinoma. [8] [9] [10] In the only published phase III randomized trial of AT that included patients with HC, and in the recently completed phase III trial of gemcitabine plus oxaliplatin in BTC, there was no significant survival benefit noted. 14, 15 Herein, we sought to determine the role of AT in resected HC by evaluating a large group of patients undergoing treatment with curative intent from the U.S. Extrahepatic Biliary Malignancy Consortium. We hypothesized that AT would improve both and recurrence free (RFS) and overall survival (OS) in resected HC.
| METHODS

| Patient population
Our data source included all patients who underwent operative intervention with curative intent for extrahepatic biliary malignancy 
| Statistical methods
The probability of OS and RFS were calculated in the method of Kaplan and Meier and analyzed using multivariate Cox regression analysis. 16, 17 Multivariate modeling was used to assess the impact of selected variables on both OS and RFS. Clinical judgment was used to select variables to evaluate from our dataset on univariate survival analysis, and these same variables were applied to our multivariate survival analysis. Patients who received AT were propensity score matched to patients who did not in a 1:1 ratio using variables which were found to be significantly associated with survival following resection (ie, patient age, ASA, lymph node status, and grade) in the multivariable analysis.
Propensity score matching was accomplished using a greedy matching algorithm with a caliper distance of 0.2 standard deviations of the logit of the propensity score.
Characteristics of the patient population receiving and not receiving AT were compared. Categorical variables were compared using the Fisher exact test or χ 2 test as appropriate, and continuous variables were compared using the two-tailed t-test. Statistical significance was set at P < 0.05. STATA version 13.1 (StataCorp LP, College Station, TX) was used for data analysis. 
| Operative and pathological data
The operative and pathology data are presented in Table 1 . There was no significant difference seen between groups for method of operation, AJCC T stage, presence of lymphovascular invasion, tumor grade, and completion of preoperative diagnostic laparoscopy. 18 As depicted in Table 1 
| Postoperative data
Postoperatively, 90-day hospital readmission and location of recurrent disease were similar between groups. Length of stay was significantly greater in the no AT group at 19.5 ± 1.8 days, versus 11.2 ± 0.5 days in the AT group (P < 0.001). See Table 1 for more details.
| AT details
In the AT group (N = 129), 89 patients (69%) received combined chemoradiotherapy, 35 patients (27%) received only chemotherapy, and five patients (4%) received only radiation therapy ( Figure 1 ). See Figure 1 for further information regarding chemotherapy regimen.
| Univariate analysis of RFS/OS
Median follow up after resection for the group was 19.8 months. RFS
for the group as a whole was 13.5% at 5 years, with a 16.3 month 
| Multivariate Cox regression modeling of RFS
Utilizing multivariate Cox regression analysis we created a model to evaluate RFS and OS (Table 2) 
| Multivariate Cox regression modeling of OS
AT (P = 0.014, HR 0.58) was found to significantly predict improved OS. The benefit seen with AT on OS is further displayed in Table 2 . LN positive final pathology (P = 0.002, HR 1.95), increased age (P = 0.011, HR 1.02), and undifferentiated pathology (P = 0.029, HR 9.97) were all found to significantly predict decreased OS. Tumor size >20 mm (P = 0.587, HR 1.12), R1 versus R0 resection status (P = 0.372, HR 1.21), higher ASA classification (P = 0.073, HR 0.69), concomitant liver resection (P = 0.727, HR 1.08), moderately differentiated pathology (P = 0.573, HR 1.14), and poorly differentiated pathology (P = 0.166, HR 1.44) were found to be non-significant predictors of OS on multivariate analysis.
| Propensity matching of AT and no AT groups
We next matched patients who received AT to those who did not based on age, LN status, ASA, and tumor grade using propensity scores (Supplementary Table S1 ). We matched based on these variables because they were the only independent predictors of survival in our multivariate analysis (Table 2) 
| Multivariate Cox regression modeling subgroup analysis of OS
The multivariate analysis was redone separating chemotherapy and chemoradiotherapy, with both groups demonstrating a similar OS benefit (both HR 0.6) to the combined analysis shown in Table 2 (HR 0.58). When only LN positive patients were included in the multivariate model, AT continued to be associated with improved OS (HR 0.28, P = 0.001). When only node negative patients were included in the model, AT was no longer significantly associated with improved OS (HR 0.76, P = 0.26).
| DISCUSSION
To our knowledge, our current analysis represents the largest in a
Western cohort that explores the role of AT on outcomes in resected HC. The majority of the patients in our study who underwent AT received both chemotherapy and radiation therapy (69%), with 27%
only receiving chemotherapy and the rest only radiation therapy.
Although AT had no survival benefit on univariate analysis, likely reflecting the increased rate of nodal positivity and R1 resection margin in this group (Table 1) In contrast to this study, our present analysis evaluates a more modern cohort of patients representing contemporary surgical outcomes (see Table 3 for further comparison details). Of note, the 5-year median survival of 21.7 months in our patient cohort is lower than prior studies. This is likely reflective of different patient populations with variable tumor biology. For instance, our mean age was 65 ± 11 years. Takada et al excluded patients 75 years or older and had a mean population age of 61, similar to other studies. 7, 14, 20, 21 In addition, each study represented a different FIGURE 2 Overall and recurrence-free survival based on adjuvant therapy status for propensity-matched patients KRASNICK ET AL.
| 369 population with specific exclusion criteria. 9, 14, 20, 21 Our data are in line with a study from Matsuo et al who examined 157 patients with resected HC, and showed that LN positivity and worse tumor grade imparted significantly decreased survival. 4 Our demonstration of decreased OS and RFS for patients with positive LNs is consistent with many prior studies. 4, 7, 9, 10 Matsuo et al also linked concomitant hepatectomy with improved survival for HC, although this was not supported by our data. 4 Of note, R0 resection was not an independent predictor of improved survival on multivariate analysis. This contrasts with prior reports. 3, 4, 10 However, it is consistent with other data that demonstrated no appreciable independent benefit with R0 resection. 7, 20, 21 Our lack of benefit for R0 resection may be due to the relatively high use of AT, which was more likely to be used after an R1 resection. In addition, our rate of node positive resection for the cohort was 37%, which is comparable to several prior studies, but is significantly greater than others, such as the retrospective study by Kang et al that reported a 25% LN positivity rate. 7, 8, 10 Our study is limited by its retrospective nature. Although we strived to created concise definitions across the member institutions that would easily allow translation from each hospital system, we acknowledge that there are cases where the coded data would likely differ depending upon the reviewer. In addition, we recognize that the 15 year collection period over multiple centers leads to considerable patient and treatment heterogeneity. Although we acknowledge these drawbacks to our dataset, the relatively large number of patients included in our study, in combination with the fact that 2000-2015 represents a more modern cohort than most prior Western studies, we do feel that our analysis fills a significant gap in the literature. 13, 22 Our data also lacks significant detail regarding chemotherapy regimens (see Figure 1) , with only 34% of the patients receiving chemotherapy in our database having a defined regimen. This is a function of the limited granularity afforded by our retrospective database. Although we feel that these missing 66% of regimens from 10 academic centers from 2000 to the 2015 likely represent variations of fluorouracil/ gemcitabine based therapy, we are unable to make strong specific recommendations.
Our conclusions are strengthened by our propensity matched analysis, and although the number of patients was insufficient to match for all preoperative variables, we were able to match for all variables that were significant in our multivariate model. plus platinum based chemotherapy. 23, 24 Gemcitabine plus cisplatin has a category 1 recommendation per NCCN guidelines for advanced/ metastatic disease. 12 Our data support the use of AT after resection of node positive HC, and with the adoption of updated chemotherapy regimens we are hopeful for future improvement in survival.
Our multi-institutional study of 249 patients who underwent resection for HC, shows an association of AT and improved survival both on multivariate and propensity matched analysis, with the effect limited to those with node positive disease. It is likely that with the discovery of more active regimens in HC, AT will be more effective and incorporated into future treatment protocols.
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